HLA-haploidentical hematopoietic SCT (HSCT) provides an opportunity for almost all patients who lack HLA-matched sibling donors. The donor availability can be increased by including the collateral related donors (CRDs). We compared clinical outcomes of patients with hematological malignancies, who underwent haploidentical HSCT from CRD (n ¼ 30) and immediate related donors (IRDs; n ¼ 120). In CRDs, 29 (96.7%) patients achieved sustained engraftment. In CRDs and IRDs, the median times of myeloid recovery were 13 (range 10-20 days) and 14 days (range 12-23 days), and the median times of platelet recovery were 18 (range 7-270) and 15 days (range 7-132 days; P ¼ 0.027). The incidences of II-IV acute GVHD were 27.6% versus 39.4% (P ¼ 0.058). The 2-year cumulative incidences of chronic GVHD (cGVHD) were 63.3% versus 57.8% (P ¼ 0.365). The 2-year incidence of extensive cGVHD of CRDs was significantly higher than that of IRDs (36.7% versus 20.2%, P ¼ 0.03). The 2-year incidences of relapse, 3-year probability of OS and leukemia-free survival for the two groups were 26.7% versus 14.8% (P ¼ 0.17), 56.7% versus 70.4% (P ¼ 0.224) and 50.0% versus 65.4% (P ¼ 0.103), respectively. This study shows that haploidentical HSCT from CRDs can provide a safe and effective treatment for patients with hematological malignancies. CRDs could be an alternative when there was no suitable IRDs.
INTRODUCTION
Up to now, allogeneic hematopoietic SCT is still the only way to cure many hematological malignancies. However, many patients cannot find an HLA-matched sibling donor. Haploidentical HSCT provides an opportunity for almost all patients to find an adequate donor. Mismatched family donors offer several advantages: (1) provide an immediate and easy accesss to obtain stem cells for urgent diseases; (2) have an ability to select the best of relatives based on the age, infectious disease status; 1,2 (3) give an optimal graft composition; and (4) an immediate access to donor-derived cellular therapies, if needed. Besides immediate family donors (parents, children, and half siblings), the collateral relatives such as uncles, aunts, nephews, nieces and cousins could be potential HLA-haploidentical donors. This extends the choice of HLA-haploidentical donors without suitable immediate family donor. There has been no report stressing HLA-haploidentical HSCT from collateral related donors (CRDs) until now.
In recent years, we have developed a novel approach to HLAmismatched/haploidentical blood and BMT using G-CSF-primed BM (G-BM) plus G-CSF-mobilized PBSCs without in vitro T-cell depletion after conditioning with a modified BU/CY2 plus thymoglobuline (antithymocyte globulin) regimen (the GIAC protocol). [3] [4] [5] By this protocol, promising results have been achieved. [6] [7] [8] [9] In this study, we compared the clinical outcomes of patients with hematological malignancies who underwent HLAhaploidentical HSCT, between CRD (n ¼ 30) and immediate related donor (IRD) groups (n ¼ 120) in the GIAC protocal.
MATERIALS AND METHODS Patients
Cases were identified from a cohort of 885 patients who underwent haploidentical allogeneic HSCT between August 2005 and June 2011 at the Peking University Institute of Hematology, Beijing, China. A total of 30 patients with hematological malignancies received HLA-haploidentical HSCT from CRDs. For each case, multiple controls (one to four) were randomly selected from the patients who underwent HLA-haploidentical HSCT and were matched according to the following criteria: age at the time of HSCT (±5 years) and year of the HSCT (±2 years). There were no statistical differences in age, gender of the patients, degree of HLA matching, diagnosis, status of disease between the two groups. Two of the 30 patients received a second HSCT from the same donor; among them, 1 received HSCT at 45 days after the first HSCT because of graft failure and the other 1 received it at 240 days because of relapse of leukemia.
Donors
HLA-A and HLA-B typing was performed by intermediate-resolution DNA typing, whereas HLA-DRB1 typing was performed using high-resolution DNA techniques. Donor-recipient pair was identified as HLA-haploidentical matched according to the familial spectrum of genetics analysis. Donors were ranked by priority based on the best HLA match, younger age and better health.
Conditioning regimens
A modified BU/CY þ antithymocyte globulin was used for conditioning regimen that consisted of cytarabine (4 g/m 2 Â 2 days, on day À 10 to À 9), BU (3.2 mg/kg Â 3 days, on day À 8 to À 6), CY (1.8 g/m 2 Â 2 days, on day À 5 to À 4), simustine (Me-CCNU; 250 mg/m 2 orally once on day À 3) and antithymocyte globulin (2.5 mg/kg Â 4 days, on day À 5 to À 2). One patient received the conditioning regimen including TBI (770 cGy on day À 7), fludarabine (50 mg Â 5 days, on day À 6 to À 1), Me-CCNU (250 mg/m 2 orally once on day À 3) and antithymocyte globulin (1.5 mg/ kg Â 2 days, on day À 3 to À 2) in the second HSCT. Another one received fludarabine (50 mg Â 3 days, on day À 5 to À 3) and anti-CD25 MoAbs (basiliximab, 20 mg Â 2 days, on day 1 and 4) in the second HSCT.
Donor priming regimen and collection of hematopoietic stem cells Donors received recombinant human G-CSF (5 mg/kg/day) for 5 days to collect G-BM and G-CSF-mobilized PBSCs. G-BM was collected on day 4 after G-CSF and G-CSF-mobilized PBSCs on day 5. The target mononuclear cell count was X6 Â 10 8 /kg of recipient weight. Fresh unmanipulated G-BM and G-CSF-mobilized PBSCs were infused into the recipient on the day of collection. In the instances of ABO major blood group incompatibility, red cells were removed by density gradient sedimentation with Hespan.
Supportive care
All patients were cared for in single rooms with HEPA-filtered air and received prophylactic antibiotics if their ANC was o1 Â 10 9 /l. Fluconazole was given to all patients from day À 5 to day 30. Trimethoprim/ sulfamethoxazole was administered for prophylaxis against Pneumocystis jiroveci infection. Acyclovir was given as herpes prophylaxis from day 1 until day 180. Patients were monitored weekly for CMV infection by PCR. CMV-positive patients were treated with either ganciclovir or foscarnet. Blood products were irradiated before infusion.
GVHD prophylaxis and treatment
GVHD prophylaxis regimen consisted of CsA, mycophenolate mofetil and short-term MTX. CsA (1.25 mg/kg) was given from day À 9 i.v. and switched to oral formulation as soon as the patient was able to take medicine after engraftment. The dosage of CsA was adjusted according to the serum level to maintain a level between 150 and 250 ng/ml. The dosage of MTX was administered i.v. at a dosage of 15 mg/m 2 on day 1 and 10 mg/m 2 on day 3, 6 and 11 post transplantation. The dosage of mycophenolate mofetil was 0.5 g every 12 h administered orally from day À 9 before transplantation to day 30 after transplantation. The criteria for grading acute GVHD (aGVHD) and chronic GVHD (cGVHD) were according to previously published studies. 10, 11 aGVHD was treated with steroids (methylsprednisolone (0.5-1 mg/kg per day)). When the grade of aGVHD was II or greater, MTX was added whenever needed. If there was either inadequate or no response to primary therapy, anti-CD25 MoAb was administered.
Engraftment
Neutrophil engraftment was defined as an ANC exceeding 0.5 Â 10 9 /I for 3 consecutive days and platelet engraftment as exceeding 20 Â 10 9 /I for 7 consecutive days without transfusion support.
DLI and imatinib
When hematologic or cytogenetic relapse was diagnosed after transplantation, the relapse was treated with a trial phase of immunosuppressant withdrawal, followed by therapeutic DLI. Acute leukemia patients whose blast count in the BM at the time of post-HSCT relapse was 420% received prior chemotherapy.
12 DLI was given 48 h after the last chemotherapy dose. For patients whose blastcount was o20%, DLI was given without chemotherapy, after immunosuppression had been discontinued for a minimum of 2 weeks and there was no evidence of active GVHD. In very high-risk patients (patients with acute leukemia in the nonremission state before HSCT), patients with mixed chimerism and patients with signs of minimal residual disease, prophylactic DLI was given without prior chemotherapy. All patients received short-term immunosuppressive agents for 2-4 weeks for the prevention of DLI-associated GVHD.
Imatinib mesylate was given to CML or Ph chromosome-positive ALL patients who experienced a cytogenetic or hematologic relapse after HSCT and to patients who showed rising levels (1 log increase) of bcr/abl RNAtranscripts by real-time quantitative PCR.
Statistical analysis
When groups were compared according to continuous covariates, MannWhitney's U-tests were used. A w 2 -test was used to compare categorical covariates. The probabilities of OS, leukemia-free survival, nonrelapse mortality (NRM) and relapse rate were estimated by the Kaplan-Meier method. Potential prognostic factors for OS, relapse rate and NRM were evaluated in univariate analyses by the log-rank test, with a P-valueo0.05 considered statistically significant. All statistical analyses were done by SPSS 18.0 (SPSS Inc., Chicago, IL, USA).
Definitions and assessments
Patients were classified as standard risk if they were in first or second CR (CR1 or CR2) without high-risk cytogenetics, 13 such as t(4;11) or t(9;22), or if they had chronic-phase CML or myelodysplastic syndrome. Patients in CR3 or beyond, nonremission, or CR1 with high-risk cytogenetics, or those with CML beyond the chronic phase were classified as high risk.
All patients were scheduled to have their BM samples examined morphologically, as well as analyzed by cytogenetic and flow cytometric techniques at þ 1, þ 2, þ 3, þ 4.5, þ 6, þ 9 and þ 12 months post transplantation and at 6 month intervals thereafter, or as clinically indicated. Relapse was defined by morphologic evidence of disease in peripheral blood, BM or extramedullary sites, or by the recurrence and sustained presence of pre-transplantation chromosomal abnormalities. Leukemia-free survival was defined as survival in continuous CR.
RESULTS

Characteristics of patients and donors
The characteristics of cases and controls are summarized in Table 1 . In the CRD group, the median age of patients was 25 years (range 3-56) old.There were 16 men and 14 women. Fourteen patients had ALL; of them, 7 patients were positive with t (9;22), 12 patients had AML, 2 patients had CML and 2 had myelodysplastic syndrome classified as refractory anemia with excess blasts. A total of 19 (63.3%) patients belong to the standard risk group and the other 11 (36.7%) patients belong to the highrisk group. The median time from diagnosis to HSCT was 187 days (range 39-480). The median age of donors was 30 years (range 18-55) old. Twenty-three donors were men and seven were women. Among the donors, 17 (56.7%) were cousins, 9 were uncles or aunts and 4 were nephews or nieces of the recipents. Of all 30 donor/recipent pairs, 15 (50.0%) were mismatched in 3 HLA loci, 14 (46.7%) in 2 loci and 1 (3.3%) in 1 locus. There were no statistical differences in age, gender of the patients, donorrecipient sex match, ABO-typing match, degree of HLA matching, diagnosis, status of disease before transplantation, duration of disease and follow-up time between the two groups. The percent of patients who received DLI in the CRD group (26.7%) was higher than that in the IRD group (12.5%).
Engraftment
At least two of three methods (HLA DNA typing, PCR-DNA finger printing and FISH) were used to confirm 100% donor chimerism. In the CRD group, 29 (96.7%) patients achieved sustained engrafment with full donor chimerism. One patient with CMLaccelerated phase, who underwent HSCT from his aunt had graft failure and received a second HSCT from the same donor at 45 days after the first HSCT. He died of infection at 48 days after the second infusion without engraftment. The median numbers of mononuclear cell count (MNC) and CD34 þ infused at transplantation of CRD HSCT were 7.6 (4.8-11.8) Â 10 8 and 2.1 (1.1-8.2) Â 10 6 /kg, respectively. All cases of the control group achieved sustained engrafment. The median times of myeloid recovery of the two groups were 13 (range 10-20 days) and 14 days (range 12-23 days) after transplantation, respectively. A total of 26 (86.7%) and 110 (91.7%) patients achieved platelet engraftments in CRD and IRD groups, respectively. The median times of platelet recovery were 18 (range 7-270 days) and 15 days (range 7-132 days), respectively (P ¼ 0.027). The time of myeloid or platelet recovery had no association with the extent of HLA disparity and the number of MNC and CD34 þ cell infusion.
GVHD
At day 100 after transplantation, the cumulative incidences of grade II-IV aGVHD and grade III-IV aGVHD for the CRD and IRD groups were 27.6% versus 39.4% (P ¼ 0.058, Figure 1 ) and 10.3% versus 28.3%, respectively (P ¼ 0.178).
A total of 28 patients of the CRD group and 112 of the IRD group survived more than 100 days after transplantation and were evaluated for cGVHD. The 2-year cumulative incidences of cGVHD for the CRD and IRD groups were 63.3% (95% confidence interval (CI), 46.6-79.9%) and 57.8% (95% CI, 48.2-67.4%), respectively (P ¼ 0.365, Figure 2 ). The 2-year cumulative incidence of extensive cGVHD of the CRD group was significantly higher than that of the IRD group (36.7% (95% CI, 33.4-40.1%) versus 20.2% (95% CI, 19.1-21.3%), P ¼ 0.03, Figure 3 ).
Univariate and multivariate analyses showed that the factors had no influence on the incidence of aGVHD and cGVHD, including age, gender of the patients and donors, degree of HLA matching, relationship of donor-recipient, donor-recipient 80.00 100.00 Figure 1 . Cumulative incidence of II-IV acute GVHD in the CRD and IRD groups. sex match, ABO match, status of disease before transplantation, duration of disease and the number of MNC and CD34 cell infusion (Table 2 ). In the CRD group, the incidence of extensive cGVHD was significantly associated with received DLI (75.0% vs 27.2%, P ¼ 0.024; Figure 4 ).
Relapse
The 2-year incidences of relapse for the CRD and IRD groups were 26.7% and 14.8%, respectively (P ¼ 0.17, Figure 5 ). In the CRD group, eight (26.7%) patients had recurrent disease, which included three patients from the standard-risk group and five from the high-risk group. All of the eight patients experienced hematologic relapse and the median time of relapse was 10.1 months (range 3.0-24.6) after tranplantation. Four patients received chemotherapy followed by therapeutic DLI, two patients received chemotherapy only, one patient received imatinib mesylate and a therapeutic DLI, and one patient received the second transplantation from the same donor. Among the eight patients, two patients achieved remission and survived free of relapse with the follow-up 1560 and 970 days, respectively. The other six patients died of relapse.
Survival
The 3-year probabilities of OS for the CRD and IRD groups were 56.7% and 70.4%, respectively (P ¼ 0.224; Figure 6 ). The 3-year probabilities of leukemia-free survival for the CRD and IRD groups were 50.0% and 65.4%, respectively (P ¼ 0.103). Multivariate analyses showed that the high-risk disease status at the time of transplantation was associated with a worse OS (hazard ratio, 0.437; 95% CI, 0.232-0.823; P ¼ 0.010; Table 2 ). The relationship of donor-recipient, the extent of HLA mismatch and the occurrence of aGVHD and cGVHD had no effect on any transplantation outcome.
The 2-year incidences of NRM for the CRD and IRD cohorts were 26.7% versus 21.4% (P ¼ 0.74), respectively. As to the last followup, 16 patients of the CRD group were alive after transplantation. Overall, eight patients died of other reasons rather than relapse. Five patients died of infection, one patient died of severe aGVHD directly, one patient died of multiple organ failure and one patient died of transplant-associated thrombotic microangiopathy.
DISCUSSION
The work on HLA-haploidentical HSCT has been proceeding for over two decades all over the world; the majority of donors were immediate family donors: parents, offsprings or half-siblings in High rates of graft failure, severe GVHD and NRM are the three major obstacles for HLA-haploidentical HSCT. 16, 17 During the past two decades, substantial progress has been made in the field of HLA-haploidentical HSCT. Rizzieri et al. 18 reported an incidence of 6% graft failure for HLA-haploidentical HSCT. In the GIAC protocol, the incidence of graft failure was 0-0.4% in our previous reports. [4] [5] [6] [7] [8] In the CRD group, the incidence of graft failure was 3.3%. It reveals that HLA-haploidentical HSCT from CRDs is safe and acceptable in terms of engraftment. Although there was no significant difference in graft failure between CRD and IRD groups, a trend toward higer incidence of graft failure in the CRD group was found to exist. A large-scale study was needed to verify it. Our study found that the time of platelet recovery in the CRD group was longer than that in the IRD group, and had no association with the extent of HLA disparity and the number of MNC and CD34 þ cell infusion.
Our current study suggested that there were no significant differences in cumulative incidences of grade II-IV aGVHD and cGVHD between the two groups. We found that the incidence of extensive cGVHD in the CRD group was higher than that in the IRD group, and those who received DLI after transplantation were prone to develop extensive cGVHD. Among all 30 patients of the CRD group, 8(26.7%) cases received DLI, with 3 for prophylactic purpose and 5 for therapeutic purpose. The percent of patients of the IRD group (12.5%), who underwent DLI, was lower than that of the CRD group. This may partially explain the higher incidence of extensive cGVHD in CRD group. Further studies with more patients are needed to comfirm the association between them. There was no difference in the incidence and severity of aGVHD and cGVHD with HLA disparity, which was consistent with our previous results. [3] [4] [5] [6] [7] [8] [9] Although not being statistically significant, there are trends for a difference in diagnosis repartition between the CRD and IRD group (P ¼ 0.079). This may have an impact on GVHD occurrence.
In our study, the 2-year probability of relapse in the CRD group was 26.7%, 16.7% in the standard-risk group and 41.7% in the high-risk group. The results were similar to our previous reports. The 3-year probabilities of relapse in the standard-risk group were 11.9% for a AML and 24.3% for ALL, and in the high-risk group were 20.2% for AML and 48.5% for ALL. 5 Our study suggested that there was no stastistical difference in the incidence of relapse between the two groups. Advanced disease status, 5,6 a higher CD4/CD8 ratio in G-BM, 19 and delayed lymphocyte recovery at day 30 post transplantation correlated with an increased relapse rate. 20 Our study suggested that the 3-year probability of OS and leukemia-free survival for the CRD and IRD groups were 56.7% versus 70.4% and 50.0% versus 65.4%, respectively. It should be noted that even though the difference did not reach statistical significance between the two groups, a trend toward higher mortality after HLA-haploidentical HCST from CRD was found to exist. The advanced disease status was associated with a lower probability of OS. The 2-year NRM of CRD group was 26.7% and the most frequent casuse of transplantation-related deaths was opportunity infection, which was similar to our previous reports under the same protocol. Huang et al. 4 found that 39 of the 171 patients died from TRM. For CML patients, the 1-year TRM of patients in CP1, CP2/CR2, accelerated phase and blast crisis (BC) are 28.3%, 16.92%, 13.33% and 7.69%, respectively. 6 In a recent report, 250 acute leukemia patients received allografts from related donors. The 3-year TRM in standard-risk and high-risk groups was 19.4% and 29.4% for AML and 21.2% and 50.8% for ALL, respectively. 6 Aversa et al. 15, 21 reported the TRM was 40% in patients with high-risk acute leukemia, who received T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype. TRMs were dependent on disease stage at transplant and was significantly higher in patients transplanted in relapse (58% versus 36%; P ¼ 0.02). Thus, post-transplantation infectious complications remain the important barriers to overcome to further enhance the effects of HLA-haploidentical HSCT.
In conclusion, this study shows that HLA-haploidentical HSCT from CRDs can provide a safe and effective treatment for patients with hematological malignancies. CRDs could be an alternative when there was no suitable IRDs. Months after transplantation Figure 5 . Cumulative incidence of relapse for the CRD or IRD groups. 2000.00 Figure 6 . Cumulative incidence of OS after CRD or IRD HLAhaploidentical HSCT.
